This model utilized tumor cells derived from clinical patients, maintaining their original heterogeneity and cisplatin resistance, thus allowing simultaneous evaluation of the regulatory effects of FGF17 targeting on tumor growth, metabolic reprogramming, and chemosensitization. The gene discussed is FGF17; the disease is neoplasm.